What is Neurocrine Biosciences's capex?

Neurocrine Biosciences (NBIX) reported capex of $9.1M in Q1 2026.

How has Neurocrine Biosciences's capex changed year-over-year?

Neurocrine Biosciences's capex decreased by 15.0% year-over-year, from $10.7M to $9.1M.

What is the long-term trend for Neurocrine Biosciences's capex?

Over 3 years (2021 to 2025), Neurocrine Biosciences's capex has grown at a 15.9% compound annual growth rate (CAGR), from $23.4M to $36.4M.

What does capex mean?

Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.

Neurocrine Biosciences NBIX CapEx

CapEx at other companies

Bristol-Myers SquibbBMY

$347M+33.5%

Acadia PharmaceuticalsACAD

$5.21M—

Crinetics PharmaceuticalsCRNX

$820K-33.8%

Solid Biosciences Inc.SLDB

$165K+31.0%

MapLight Therapeutics, Inc. MPLT

$24K—

BridgeBio PharmaBBIO

$69K—

Other financials

Income statement

See full

Revenue$814.5M+42.2%

Gross profit$800.7M+42.1%

Operating income$193.4M+719%

Net income$197.9M+2,405%

EPS (diluted)$1.91+2,287%

Balance sheet

See full

Cash & equivalents$274.5M+35.8%

Total debt$463.5M-6.0%

Total equity$3.4B+34.4%

Total assets$4.9B+33.0%

Cash flow

See full

Operating cash flow$145.8M+125%

Free cash flow$136.7M+153%

Valuation

See full

Market cap$17.3B+30.9%

Enterprise value$17.49B+30.2%

P/E25.9×-12.1×

P/S5.6×+0.3×

Profitability

See full

Gross margin98.2%-0.3pp

Operating margin25.4%+4.9pp

Net margin21.6%+8.9pp

FCF margin26.8%+6.4pp

Returns & leverage

See full

Return on equity22.5%+10.1pp

Debt / equity0.1×-0.1×

Current ratio2.9×-0.2×

Where this comes from

Reported directly by Neurocrine Biosciences in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

The official record: Neurocrine Biosciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Neurocrine Biosciences's capex.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Neurocrine Biosciences's capex?: Neurocrine Biosciences (NBIX) reported capex of $9.1M in Q1 2026.
How has Neurocrine Biosciences's capex changed year-over-year?: Neurocrine Biosciences's capex decreased by 15.0% year-over-year, from $10.7M to $9.1M.
What is the long-term trend for Neurocrine Biosciences's capex?: Over 3 years (2021 to 2025), Neurocrine Biosciences's capex has grown at a 15.9% compound annual growth rate (CAGR), from $23.4M to $36.4M.
What does capex mean?: Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.